Arch Biopartners Inc. (ARCH.V)
CAD 1.73
(-0.57%)
CAD 1.73
(-0.57%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 703.92 Thousand CAD | -69.56% |
| 2022 | 2.31 Million CAD | -31.2% |
| 2021 | 3.36 Million CAD | -0.85% |
| 2020 | 3.39 Million CAD | 17.51% |
| 2019 | 2.88 Million CAD | 94.51% |
| 2018 | 1.48 Million CAD | 324.46% |
| 2017 | 349.44 Thousand CAD | 5.82% |
| 2016 | 330.21 Thousand CAD | 0.59% |
| 2015 | 328.27 Thousand CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | -100.0% |
| 2005 | 1661.00 CAD | -80.53% |
| 2004 | 8533.00 CAD | -91.22% |
| 2003 | 97.23 Thousand CAD | 0.0% |
| 2002 | - CAD | 0.0% |
| 2001 | - CAD | 0.0% |
| 2000 | - CAD | 0.0% |
| 1999 | - CAD | 0.0% |
| 1998 | - CAD | 0.0% |
| 1997 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 500 Thousand CAD | 0.0% |
| 2024 Q2 | 500 Thousand CAD | 0.0% |
| 2024 Q1 | 500 Thousand CAD | -28.97% |
| 2023 Q4 | 703.92 Thousand CAD | -75.54% |
| 2023 FY | 703.92 Thousand CAD | -69.56% |
| 2023 Q2 | 2.31 Million CAD | 1.08% |
| 2023 Q1 | 2.29 Million CAD | -0.93% |
| 2023 Q3 | 2.87 Million CAD | 24.27% |
| 2022 Q1 | 3.36 Million CAD | -0.01% |
| 2022 Q4 | 2.31 Million CAD | -31.18% |
| 2022 FY | 2.31 Million CAD | -31.2% |
| 2022 Q2 | 3.36 Million CAD | -0.01% |
| 2022 Q3 | 3.36 Million CAD | -0.01% |
| 2021 Q1 | 3.39 Million CAD | 0.01% |
| 2021 Q2 | 3.39 Million CAD | 0.01% |
| 2021 Q3 | 3.39 Million CAD | -0.01% |
| 2021 Q4 | 3.36 Million CAD | -0.86% |
| 2021 FY | 3.36 Million CAD | -0.85% |
| 2020 Q3 | 3.39 Million CAD | 0.13% |
| 2020 FY | 3.39 Million CAD | 17.51% |
| 2020 Q1 | 2.88 Million CAD | 0.15% |
| 2020 Q2 | 3.39 Million CAD | 17.46% |
| 2020 Q4 | 3.39 Million CAD | -0.23% |
| 2019 Q2 | 1.94 Million CAD | 34.22% |
| 2019 Q4 | 2.88 Million CAD | -2.04% |
| 2019 Q3 | 2.94 Million CAD | 51.81% |
| 2019 Q1 | 1.44 Million CAD | -2.55% |
| 2019 FY | 2.88 Million CAD | 94.51% |
| 2018 Q1 | 849.61 Thousand CAD | 143.13% |
| 2018 FY | 1.48 Million CAD | 324.46% |
| 2018 Q3 | 1.46 Million CAD | 0.96% |
| 2018 Q2 | 1.45 Million CAD | 70.68% |
| 2018 Q4 | 1.48 Million CAD | 1.31% |
| 2017 Q3 | 319.88 Thousand CAD | -4.28% |
| 2017 Q1 | 334.16 Thousand CAD | 1.19% |
| 2017 Q2 | 334.19 Thousand CAD | 0.01% |
| 2017 Q4 | 349.44 Thousand CAD | 9.24% |
| 2017 FY | 349.44 Thousand CAD | 5.82% |
| 2016 Q4 | 330.21 Thousand CAD | -0.79% |
| 2016 Q3 | 332.83 Thousand CAD | -1.59% |
| 2016 Q2 | 338.2 Thousand CAD | 1.5% |
| 2016 Q1 | 333.2 Thousand CAD | 1.5% |
| 2016 FY | 330.21 Thousand CAD | 0.59% |
| 2015 Q3 | 321.54 Thousand CAD | 1.31% |
| 2015 Q4 | 328.27 Thousand CAD | 2.09% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q2 | 317.39 Thousand CAD | 0.0% |
| 2015 FY | 328.27 Thousand CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q1 | - CAD | -100.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2006 FY | - CAD | -100.0% |
| 2006 Q4 | 1706.00 CAD | -0.47% |
| 2006 Q3 | 1714.00 CAD | 0.53% |
| 2006 Q2 | 1705.00 CAD | 2.65% |
| 2006 Q1 | 1661.00 CAD | 0.0% |
| 2005 Q4 | - CAD | -100.0% |
| 2005 Q3 | 3628.00 CAD | -28.76% |
| 2005 Q2 | 5093.00 CAD | -40.31% |
| 2005 Q1 | 8533.00 CAD | -95.83% |
| 2005 FY | 1661.00 CAD | -80.53% |
| 2004 Q3 | 283.45 Thousand CAD | 210.03% |
| 2004 Q1 | 97.23 Thousand CAD | 0.0% |
| 2004 Q2 | 91.42 Thousand CAD | -5.97% |
| 2004 FY | 8533.00 CAD | -91.22% |
| 2004 Q4 | 204.39 Thousand CAD | -27.89% |
| 2003 Q4 | - CAD | 0.0% |
| 2003 Q3 | - CAD | 0.0% |
| 2003 Q2 | - CAD | 0.0% |
| 2003 Q1 | - CAD | 0.0% |
| 2003 FY | 97.23 Thousand CAD | 0.0% |
| 2002 FY | - CAD | 0.0% |
| 2002 Q4 | - CAD | 0.0% |
| 2002 Q2 | - CAD | 0.0% |
| 2002 Q3 | - CAD | 0.0% |
| 2002 Q1 | - CAD | 0.0% |
| 2001 Q1 | - CAD | 0.0% |
| 2001 Q2 | - CAD | 0.0% |
| 2001 Q3 | - CAD | 0.0% |
| 2001 FY | - CAD | 0.0% |
| 2000 FY | - CAD | 0.0% |
| 2000 Q1 | - CAD | 0.0% |
| 1999 Q1 | - CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| 1998 FY | - CAD | 0.0% |
| 1998 Q4 | - CAD | 0.0% |
| 1998 Q2 | - CAD | 0.0% |
| 1998 Q3 | - CAD | 0.0% |
| 1997 FY | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Covalon Technologies Ltd. | 919.08 Thousand CAD | 23.41% |
| Hemostemix Inc. | 4.32 Million CAD | 83.711% |
| Universal Ibogaine Inc. | 1.73 Million CAD | 59.491% |
| Kane Biotech Inc. | 1.3 Million CAD | 45.955% |
| MedMira Inc. | 2.95 Million CAD | 76.197% |
| Marvel Biosciences Corp. | 1 Million CAD | 29.608% |
| NervGen Pharma Corp. | 105.6 Thousand CAD | -566.567% |
| XORTX Therapeutics Inc. | - CAD | -Infinity% |